Esperion Therapeutics (ESPR) Cash from Operations (2012 - 2026)
Esperion Therapeutics (ESPR) posted Cash from Operations of 27722000.0 for Q1 2026, down 161.27% on a QoQ basis from 45243000.0 in Q4 2025, and down 22.51% year-over-year from 35775830.73 in Q1 2025.
Esperion Therapeutics (ESPR) Cash from Operations (2012 - 2026) Analysis & Trends
Esperion Therapeutics' Cash from Operations history runs 15 years deep, the most recent figure standing at 27722000.0 for Q1 2026.
- Quarterly Cash from Operations fell 22.51% year-over-year to 27722000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 18187000.0 (up 81.83% YoY) and the FY2025 annual result came in at 13093000.0, up 44.65% from the prior year.
- Cash from Operations was 27722000.0 for Q1 2026 at Esperion Therapeutics, down from 45243000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 53828000.0 in Q1 2024 and bottomed at 54356000.0 in Q1 2023.
- A 5-year average of 22046058.82 and a median of 31422000.0 in 2025 frame the typical range for Cash from Operations.
- Peak annual rise in Cash from Operations reached 229.44% in 2025, while the deepest fall reached 336.11% in 2025.
- Esperion Therapeutics' Cash from Operations stood at 42472000.0 in 2022, then gained by 12.75% to 37056000.0 in 2023, then rose by 5.68% to 34952000.0 in 2024, then jumped by 229.44% to 45243000.0 in 2025, then sank by 161.27% to 27722000.0 in 2026.
- Business Quant data shows ESPR's Cash from Operations at 27722000.0 in Q1 2026, 45243000.0 in Q4 2025, and 4286000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -40.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 401.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 463.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 388.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 145.80 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.00 Mn |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | -27.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.72 Mn |
| Mar 31, 2026 | -27.72 Mn |
| Dec 31, 2025 | 45.24 Mn |
| Dec 31, 2025 | 45.24 Mn |
| Sep 30, 2025 | -4.29 Mn |
| Sep 30, 2025 | -4.29 Mn |
| Jun 30, 2025 | -31.42 Mn |
| Jun 30, 2025 | -31.42 Mn |
| Mar 31, 2025 | -22.63 Mn |
| Mar 31, 2025 | -22.63 Mn |
| Dec 31, 2024 | -34.95 Mn |
| Dec 31, 2024 | -34.95 Mn |
| Sep 30, 2024 | -35.33 Mn |
| Sep 30, 2024 | -35.33 Mn |
| Jun 30, 2024 | -7.21 Mn |
| Jun 30, 2024 | -7.21 Mn |
| Mar 31, 2024 | 53.83 Mn |
| Mar 31, 2024 | 53.83 Mn |
| Dec 31, 2023 | -37.06 Mn |
| Dec 31, 2023 | -37.06 Mn |